Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

Delayed Quote. Delayed  - 09/22 05:31:08 pm
15.5 CHF   -0.64%
09/14 NEWRON PHARMACE : Reports Half-Year 2017 Results
09/14 Newron reports half-year 2017 results
09/14 NEWRON PHARMACE : reports half-year 2017 results
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20152016Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs2.43100%5.16100% +112.52%
Sales per Regions
20152016Delta
CHF (in Million)%CHF (in Million)%
Global2.43100%5.16100% +112.52%
Managers
NameAgeSinceTitle
Stefan Weber522005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD652013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD602005Chief Medical Officer
Patrick J. Langlois, PhD722008Independent Non-Executive Director
Robert Leslie Holland MD, PhD622013Independent Non-Executive Director
Bo Jesper Hansen MD, PhD592013Independent Non-Executive Director
Joseph Donald deBethizy, PhD662014Independent Non-Executive Director
Luca Benatti, PhD562014Independent Non-Executive Director
Marco Caremi602002Executive Vice President-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 15,817,481 11,596,451 73.3% 0 0.0% 73.3%
Shareholders
NameEquities%
Investor AB 1,772,817 11.2%
Gefim SpA 1,311,957 8.29%
Aviva Plc 1,097,054 6.94%
JPMorgan Asset Management (UK) Ltd. 311,633 1.97%
UBS AG (Investment Management) 273,806 1.73%
Union Investment Privatfonds GmbH 149,140 0.94%
Polar Capital LLP 148,573 0.94%
Kairos Partners SGR SpA 140,422 0.89%
EFG Asset Management (UK) Ltd. 130,000 0.82%
Norges Bank Investment Management 121,793 0.77%
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-19.60%253
AMGEN28.70%136 186
CELGENE CORPORATION24.61%112 486
GILEAD SCIENCES15.40%107 896
REGENERON PHARMACEUTICALS19.36%46 445
VERTEX PHARMACEUTICALS107.30%38 337
ACTELION21.20%29 716
GENMAB21.65%13 900
KITE PHARMA INC300.85%10 257
EXELIXIS, INC.87.86%8 232
TESARO INC-9.56%6 430
BIOVERATIV INC0.00%6 059
BLUEBIRD BIO INC111.99%5 829
NEUROCRINE BIOSCIENCES, INC.46.77%5 190
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-12.40%4 926
JUNO THERAPEUTICS INC139.84%4 425
HUALAN BIOLOGICAL ENGINEERING INC--.--%3 882
CLOVIS ONCOLOGY INC73.23%3 761
PEPTIDREAM INC-42.76%3 733
BEIGENE LTD (ADR)179.61%3 598
BIOCON LTD12.20%3 363
Connections : Newron Pharmaceuticals SpA
European School of Management & Technology GmbH
DFC Langlois
White City Consulting ApS
Oxford Gene Technology IP Ltd.
PJL Consulting
Early Clinical Development Consulting Ltd.
LABORIE Medical Technologies, Inc.
NOXXON Pharma AG
EryDel SpA
Wellington Partners GmbH
Constantia Flexibles Group GmbH
Assobiotec
Constantia Flexibles AG
Proterris, Inc.
Azanta A/S
Universitätsklinikum Würzburg
CMC Contrast AB
Italian Angels For Biotech
MipSalus ApS
Orphazyme ApS
The European Association for Bioindustries
© 2017 People , Fundamentals and Ownership